This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Autoimmune	c-jun N-terminal kinase 1 (JNK1); JNK2 (MAPK9); tumor necrosis factor- α (TNF- α)	A study in mice suggests that inhibiting hematopoietic expression of JNK1 or JNK2 may help prevent autoimmune hepatitis. In a mouse model of fulminant hepatitis, mice lacking JNK1 and JNK2 expression in hematopoietic cells had less liver enzymes and greater protection against hepatitis than wild-type mice. Next steps could include evaluating JNK inhibitors in preclinical models of autoimmune hepatitis. CC-930, a JNK inhibitor from Celgene Corp., is in Phase I testing to treat fibrotic diseases. SciBX 2(6); doi:10.1038/scibx.2009.216 Published online Feb. 12, 2009	Patent and licensing status unavailable	Das, M. <i>et al. Cell</i> ; published online Jan. 22, 2009; doi:10.1016/j.cell.2008.11.017 Contact: Roger J. Davis, University of Massachusetts Medical School, Worcester, Mass. e-mail: roger.davis@umassmed.edu